PT3.5/CMV-EGFRvIII Citations (3)

Originally described in: De novo induction of genetically engineered brain tumors in mice using plasmid DNA.
Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL, Long C, Demorest ZL, Zamora EA, Low WC, SantaCruz K, Largaespada DA, Ohlfest JR Cancer Res. 2009 Jan 15. 69(2):431-9. PubMed Journal

---

Articles Citing PT3.5/CMV-EGFRvIII

Articles
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M. Cancers (Basel). 2019 Jul 5;11(7). pii: cancers11070947. doi: 10.3390/cancers11070947. PubMed
Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies. Tuzmen C, Cairns TM, Atanasiu D, Lou H, Saw WT, Hall BL, Cohen JB, Cohen GH, Glorioso JC. Mol Ther Methods Clin Dev. 2020 Jan 13;16:145-154. doi: 10.1016/j.omtm.2019.12.013. eCollection 2020 Mar 13. PubMed
JCI20679 suppresses the proliferation of glioblastoma stem cells by activating AMPK and decreasing NFATc2 expression levels. Ando S, Kojima N, Moyama C, Fujita M, Ohta K, Ii H, Nakata S. Mol Med Rep. 2022 Jul;26(1). pii: 238. doi: 10.3892/mmr.2022.12754. Epub 2022 May 27. PubMed

If you have published an article using this material, please email us at to have your article added to this page.